Use of the Lidocaine Patch 5% in the Treatment of Neuropathic Pain

REFERENCES

• Argoff CE. Conclusions: chronic pain studies of lido-caine patch 5% using the Neuropathic Pain Scale. Curr Med Res Opin. 2004a;20(suppl 2): S29–S31.
   Google Scholar
• Argoff CE. New analgesics for neuropathic pain: the lidocaine patch. Clin J Pain. 2000;16:S62–S66.
   PubMedGoogle Scholar
• Argoff CE, Galer BS, Jensen MP, Oleka N, Gammaitoni AR. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale. Curr Med Res Opin. 2004b;20(suppl 2): S21-S28.
   Google Scholar
• Argoff CE, Katz N, Backonja M. Treatment of postherpetic neuralgia: a review of therapeutic options. J Pain Symptom Manage. 2004c;28:396–411.
   PubMed Web of Science ®Google Scholar
• Atroshi I, Gummesson C, Johnsson R, Ornstein E, Ranstam J, Rosen I. Prevalence of carpal tunnel syndrome in a general population. JAMA. 1999;282:153–158.
   PubMed Web of Science ®Google Scholar
• Balser JR, Nuss HB, Orias DW, et al. Local anesthetics as effectors of allosteric gating. Lidocaine effects on inactivation-deficient rat skeletal muscle Na channels. J Clin Invest. 1996;98:2874–2886.
   Google Scholar
• Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella-Vaughan J, Lodewick PA, Dworkin RH. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol. 2004;61:914–918.
   PubMed Web of Science ®Google Scholar
• Baron R, Wasner G. Prevention and treatment of post-herpetic neuralgia. Lancet. 2006;367:186–188.
   PubMed Web of Science ®Google Scholar
• Basbaum AI, Fields HL. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Ann Rev Neurosci. 1984;7:309–338.
   PubMed Web of Science ®Google Scholar
• Berman SM, Justis JC, Ho MI, Ing M, Eldridge D, Gammaitoni A. Lidocaine patch 5% (Lidoderm®) improves common pain qualities reported by patients with HIV-associated painful peripheral neuropathy: an open-label pilot study using the Neuropathic Pain Scale. Presented at the 10th World Congress of Pain; 2002.
   Google Scholar
• Besson JM, Chaouch A. Peripheral and spinal mechanisms of nociception. Physiology Reviews. 1987; 67:67–186.
   PubMed Web of Science ®Google Scholar
• Black JA, Cummins TR, Plumpton C, et al. Upregu-lation of a silent sodium channel after peripheral, but not central, nerve injury in DRG neurons. J Neuro-physiol. 1999;82:2776–2785.
   Google Scholar
• Burch F, Codding C, Patel N, Sheldon E. Lidocaine patch 5% improves pain, stiffness, and physical function in osteoarthritis pain patients. A prospective, multicenter, open-label effectiveness trial. Osteoarthritis Cartilage. 2004;12:253–255.
   PubMed Web of Science ®Google Scholar
• Byers MR, Bonica JJ. Peripheral pain mechanisms and nociceptor plasticity. In: Loeser JD, ed. Bonica's Management of Pain. 3rd ed. Philadelphia: Lippin-cott Williams & Wilkins; 2001:26–72.
   Google Scholar
• Carpenter MB. Core Text of Neuroanatomy. Baltimore, MD: Wiliams & Wilkins; 1978.
   Google Scholar
• Cayley WE, Jr. Antidepressants for the treatment of neuropathic pain. Am Fam Physician. 2006;73:1933–1934.
   Google Scholar
• Chen Z, Ong BH, Kambouris NG, Marban E, Tomaselli GF, Balser JR. Lidocaine induces a slow inactivated state in rat skeletal muscle sodium channels. J Physiol. 2000;524 Pt 1:37–49.
   Google Scholar
• Collins SD, Chessell IP. Emerging therapies for neuropathic pain. Expert Opin Emerg Drugs. 2005; 10:95–108.
   PubMedGoogle Scholar
• Comer AM, Lamb HM. Lidocaine patch 5%. Drugs. 2000;59:245–249.
   PubMed Web of Science ®Google Scholar
• Dalpiaz AS, Dodds TA. Myofascial pain response to topical lidocaine patch therapy: case report. Journal of Pain & Palliative Care Pharmacotherapy. 2002; 16:99–104.
   PubMedGoogle Scholar
• Dalpiaz AS, Lordon SP, Lipman AG. Topical lidocaine patch therapy for myofascial pain. Journal of Pain & Palliative Care Pharmacotherapy. 2004;18:15–34.
   PubMedGoogle Scholar
• Davis MDP. Lidocaine patch helpful in managing the chronic pain of leg ulceration. Journal of the American Academy Dermatology. 2003;49:964.
   Google Scholar
• Davis MDP, Sandroni P. Lidocaine patch for pain of erythromelalgia. Arch Dermatol. 2002;138:17–19.
   Google Scholar
• Davis MDP, Sandroni P. Lidocaine patch for pain of erythromelalgia: follow-up of 34 patients. Arch Dermatol. 2005;141:1320–1321.
   PubMedGoogle Scholar
• Devers A, Galer BS. Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study. Clin J Pain. 2000;16:205–208.
   PubMed Web of Science ®Google Scholar
• Devor M. Sodium channels and mechanisms of neuropathic pain. J Pain. 2006;7:S3–S12.
   PubMed Web of Science ®Google Scholar
• Devor M, Govrin-Lippmann R, Angelides K. Na+ channel immunolocalization in peripheral mammalian axons and changes following nerve injury and neuroma formation. JNeurosci. 1993;13:1976–1992.
   PubMed Web of Science ®Google Scholar
• Djouhri L, Koutsikou S, Fang X, McMullan S, Lawson SN. Spntaneous pain, both neuropathic and inflammatory, is related to frequency of spontaneous firing in intact C-fiber nociceptors. J Neurosci. 2006;26:1281–1292.
   PubMed Web of Science ®Google Scholar
• Dworkin R, Hart-Gouleau S, Galer B, Gammaitoni A, Domingos J. Effectiveness and impact on quality of life of the lidocaine patch 5% in painful diabetic neuropathy patients with or without allodynia [abstract]. J Pain. 2003a;42:35.
   Google Scholar
• Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003b;60:1524–1534.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Kratz KM, Litchy WJ, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study. Neurology. 1993;43:817–824.
   PubMed Web of Science ®Google Scholar
• Endo Pharmaceuticals I. Lidoderm® (lidocaine patch 5%). 2004.
   Google Scholar
• Fields HL, Basbaum AI. Central nervous system mechanisms of pain modulation. In: Wall PD, Melzack R, eds. Textbook of Pain. 3rd ed. New York: Churchill Livingstone; 1994:243–257.
   Google Scholar
• Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol Dis. 1998;5:209–227.
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: An evidence based proposal. Pain. 2005;118:289–305.
   PubMed Web of Science ®Google Scholar
• Fraenkel L, Bogardus ST, Concato J, Felson DT, Wittink DR. Patient preferences for treatment of rheumatoid arthritis. Ann Rheum Dis. 2004a;63: 1372–1378.
   Google Scholar
• Fraenkel L, Bogardus ST Jr, Concato J, Wittink DR. Treatment options in knee osteoarthritis: the pa-tient's perspective. Arch Intern Med. 2004b;164: 1299–1304.
   Google Scholar
• Galer B, Kivitz A, Fairfax M, Sheldon E, Oleka N, Gammaitoni A. A randomized open-label study comparing the efficacy and safety of lidocaine patch 5% with celecoxib 200 mg in patients with pain from osteoarthritis of the knee [abstract]. J Pain. 2005a; 6:S51.
   Google Scholar
• Galer B, Oleka N, Gammaitoni A. Lidocaine patch 5% improves outcomes for low-back pain and osteo-arthritis patients receiving COX-2 selective or traditional NSAID therapy for pain relief [abstract]. J Pain. 2005b;6:S50.
   Google Scholar
• Galer BS. Topical medications. In: Loeser JD, ed. Bonica's Management of Pain. 3rd ed. 2001: 1736–1741.
   Google Scholar
• Galer BS, Gammaitoni AR. More than 7 years of consistent neuropathic pain relief in geriatric patients. Arch Intern Med. 2003;163:628.
   PubMed Web of Science ®Google Scholar
• Galer BS, Gammaitoni AR. Use of Topiceuticals (Topically Applied, Peripherally Acting Drugs) in the Treatment of Chronic Pain. Current Drug Therapy. In Press.
   Google Scholar
• Galer BS, Gammaitoni AR, Oleka N, Jensen MP, Argoff CE. Use of the lidocaine patch 5% reduces intensity of various pain qualities reported by patients with low-back pain. Curr Med Res Opin. 2004; 20(suppl 2): S5-S12.
   Google Scholar
• Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain. 1999;80:533–538.
   PubMed Web of Science ®Google Scholar
• Gammaitoni A, Galer B, Burch F. Effectiveness and safety of the lidocaine patch 5% as monotherapy in patients with pain from osteoarthritis of the knee [abstract]. J Pain. 2003;4:78.
   Google Scholar
• Gammaitoni A, Oleka N, Galer B. Lidocaine patch 5% improves outcomes for post-herpetic neuralgia patients receiving COX-2/anti-inflammatory, opioid, or adjuvant analgesics [abstract]. J Pain. 2005;6:S49.
   Google Scholar
• Gammaitoni AR, Alvarez NA, Galer BS. Pharma-cokinetics and safety of continuously applied lidocaine patches 5%. Am J Health Syst Pharm. 2002;59:2215–2220.
   PubMed Web of Science ®Google Scholar
• Gammaitoni AR, Davis MW. Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother. 2002;36:236–240.
   PubMed Web of Science ®Google Scholar
• Gammaitoni AR, Galer BS, Onawola R, Jensen MP, Argoff CE. Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the Neuropathic Pain Scale. Curr Med Res Opin. 2004;20(suppl 2): s13-s19.
   Google Scholar
• Gimbel J, Hale M, Linn R, Galer B, Kurkimills E, Gammaitoni A. Lidocaine patch 5% in patients with acute/subacute and chronic low back pain: impact on pain intensity, pain relief, and pain interference with quality of life [abstract]. J Pain. 2003;4:71.
   Google Scholar
• Gimbel J, Linn R, Hale M, Nicholson B. Lidocaine patch treatment in patients with low back pain: results of an open-label, nonrandomized pilot study. Am J Ther. 2005;12:311–319.
   PubMedGoogle Scholar
• Gold MS. Sodium channels and pain therapy. Curr Opin Anaesthesiol. 2000;13:565–572.
   Google Scholar
• Guazzi MD, Campodonico J, Celeste F, et al. Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction. Clin Pharmacol Ther. 1998;63:79–86.
   PubMed Web of Science ®Google Scholar
• Gurwitz JH, Avorn J, Bohn RL, Glynn RJ, Monane M, Mogun H. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA. 1994;272:781–786.
   PubMed Web of Science ®Google Scholar
• Herrmann DN, Barbano RL, Hart-Gouleau S, Pennella-Vaughan J, Dworkin RH. An open-label study of the lidocaine patch 5% in painful idiopathic sensory polyneuropathy. Pain Med. 2005;6:379–384.
   PubMed Web of Science ®Google Scholar
• Hille B. Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. Journal of General Physiology. 1977;69:497–515.
   PubMed Web of Science ®Google Scholar
• Hughes RA. Peripheral neuropathy. BMJ. 2002;324:466–469.
   PubMed Web of Science ®Google Scholar
• Jensen MP. Introduction: chronic pain studies of the lidocaine patch 5% using the neuropathic pain scale. Curr Med Res Opin. 2004;20(suppl 2): S1-S4.
   Google Scholar
• Johnson AG, Seideman P, Day RO. Adverse drug interaction with nonsteroidal anti-inflammatory drugs (NSAIDs). Drug Saf. 1993a;8:99–127.
   PubMed Web of Science ®Google Scholar
• Johnson AG, Simons LA, Simons J, Friedlander Y, McCallum J. Non-steroidal anti-inflammatory drugs and hypertension in the elderly: a community-based cross-sectional study. J Clin Pharmacol. 1993b;35: 455–459.
   Google Scholar
• Kalso E. Sodium channel blockers in neuropathic pain. Curr Pharm Des. 2005;11:3005–3011.
   PubMed Web of Science ®Google Scholar
• Kanazi GE, Johnson RW, Dworkin RH. Treatment of postherpetic neuralgia: an update. Drugs. 2000;59:1113–1126.
   PubMed Web of Science ®Google Scholar
• Katz N, Davis MW, Dworkin R. Topical lidocaine patch produces a significant improvement in quality of life indicators in treated PHN patients: results of a multicenter open-label trial [abstract]. Pain Med. 2001;2:342–243.
   Google Scholar
• Koopmans PP, Thien T, Thomas CM, Van den Berg RJ, Gribnau FW. The effects of sulindac and indo-methacin on the anti-hypertensive and diuretic action of hydrochlorothiazide in patients with mild to moderate essential hypertension. Br J Clin Pharmacol. 1986;21:417–423.
   PubMed Web of Science ®Google Scholar
• LaMotte C. Distribution of the tract of Lissauer and the dorsal root fibers in the primate spinal cord. J Comp Neurol. 1977;172:529–561.
   PubMed Web of Science ®Google Scholar
• Lilly. CYMBALTA®. August 22, 2006.
   Google Scholar
• Lipman A, Dalpiaz A, Lordon S. Topical lidocaine patch therapy for myofascial pain [abstract]. J Pain. 2002;3:46.
   Google Scholar
• Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain. 2003;106:151–158.
   PubMed Web of Science ®Google Scholar
• Millan MJ. The induction of pain: an integrative review. Prog Neurobiol. 1999;57:1–164.
   PubMed Web of Science ®Google Scholar
• Nalamachu S, Crockett RS, Gammaitoni AR, Gould EM. A comparison of the lidocaine patch 5% vs. naproxen 500 mg bid for the relief of pain associated with carpal tunnel syndrome: a 6-week, randomized, parallel-group study. Medscape General Medicine. 2006;8:3.
   Google Scholar
• Nalamachu S, Crockett RS, Mathur D. Lidocaine patch 5% for carpal tunnel syndrome: How it compares with injections: A pilot study. J Fam Pract. 2006b; 55:209–214.
   PubMed Web of Science ®Google Scholar
• Nicholson B, Galer BS, Oleka N, Gammaitoni AR. A randomized open-label study comparing the effficacy and safety of lidocaine patch 5% with celecoxib 200 mg in patients with chronic axial low-back pain [abstract]. Arthritis Rheum. 2005;52:S523–S524.
   Google Scholar
• Nordin M, Nystrom B, Wallin U, Hagbarth KE. Ectopic sensory discharges and paresthesiae in patients with disorders of peripheral nerves, dorsal roots and dorsal columns. Pain. 1984;20:231–245.
   PubMed Web of Science ®Google Scholar
• Nystrom B, Hagbarth KE. Microelectrode recordings from transected nerves in amputees with phantom limb pain. Neurosci Lett. 1981;27:211–216.
   PubMed Web of Science ®Google Scholar
• Ochoa J, Torebjork HE, Culp WJ, Schady W. Abnormal spontaneous activity in single sensory nerve fibers in humans. Muscle and Nerve. 1982;5:S74–S77.
   Google Scholar
• Papanicolaou GD, McCabe SJ, Firrell J. The prevalence and characteristics of nerve compression symptoms in the general population. Journal of Hand Surgery [Am]. 2001;26:460–466.
   PubMed Web of Science ®Google Scholar
• Pertin M, Ji RR, Berta T, et al. Upregulation of the voltage-gated sodium channel b2 subunit in neuropathic pain models: characterization of expression in injured and non-injured primary sensory neurons. J Neurosci. 2005;25:10970–10980.
   PubMed Web of Science ®Google Scholar
• Pfizer I. Neurontin® (gabapentin) Capsules. December, 2005.
   Google Scholar
• Pfizer I. LYRICA® (pregabalin). March, 2006.
   Google Scholar
• Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain. 1996;65:39–44.
   PubMed Web of Science ®Google Scholar
• Sandtner W, Szendroedi J, Zarrabi T, et al. Lidocaine: a foot in the door of the inner vestibule prevents ultra-slow inactivation of a voltage-gated sodium channel. Mol Pharmacol. 2004;66:648–657.
   Google Scholar
• Sawynok J. Topical and peripherally acting analgesics. Pharmacol Rev. 2003;55:1–20.
   PubMed Web of Science ®Google Scholar
• Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18:350–354.
   PubMed Web of Science ®Google Scholar
• Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999; 83:389–400.
   PubMed Web of Science ®Google Scholar
• Sluiter JK, Rest KM, Frings-Dresen MH. Criteria document for evaluating the work-relatedness of upper-extremity musculoskeletal disorders. Scand J Work Environ Health. 2001;27:1–102.
   PubMed Web of Science ®Google Scholar
• Terman GW, Bonica JJ. Spinal mechanisms and their modulation. In: Loeser JD, Butler SH, Chapman CR, Turk DC, eds. Bonica's Management of Pain. 3rd ed.
   Google Scholar
• Philadelphia: Lippincott, Williams, & Wilkins; 2006:73–152.
   Google Scholar
• Wang SY, Mitchell J, Moczydlowski E, Wang GK. Block of inactivation-deficient Na+ channels by local anesthetics in stably transfected mammalian cells: evidence for drug binding along the activation pathway. Journal of General Physiology. 2004; 124:691–701.
   PubMed Web of Science ®Google Scholar
• Wasner G, Kleinert A, Binder A, Schattschneider J, Baron R. Postherpetic neuralgia: Topical lidocaine is effective in nociceptor-deprived skin. J Neurol. 2005;252:686.
   Google Scholar
• Waxman SG, Dib-Hajj S, Cummins TR, Black JA. Sodium channels and pain. Proc Natl Acad Sci USA.
   Google Scholar
• White WT, Patel N, Drass M, Nalamachu S. Lidocaine patch 5% with systemic analgesics such as gaba-pentin: a rational polypharmacy approach for the treatment of chronic pain. Pain Med. 2003;4:321–330.
   PubMed Web of Science ®Google Scholar
• Willis WD. The Pain System: the Neural Basis of Noci-ceptive Transmission in the Mammalian Nervous System. Basel: Karger; 1985.
   Google Scholar
• Wong DG, Spence JD, Lamki L, Freeman D, McDonald JWD. Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. Lancet. 1986;00:997–1001.
   Google Scholar